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Abstract: The release of drugs from solid drug delivery 
materials has been studied intently in recent years. 
Quantitative analyses achieved from in vitro dissolution 
becomes easier if a zero-order mathematical model is 
used. Non-gelatin nutraceutical hard-shell capsules 
of zero size (approximately 0.7-0.8 cm) were produced 
from carrageenan-based natural polymers, namely 
carrageenan-alginate (CA) and carrageenan-starch (CS). 
Disintegration, dissolution and zero-order drug release 
kinetics of hard-shell capsules containing 100 mg of 
salicylamide were studied. The disintegration time of CA 
and CS were observed to be less than 30 min for both CA and 
CS. In vitro dissolution profile showed that the percentage 
dissolution of CA capsules was better at pH 4.5, while that 
of CS was poor at pH 1.2, 4.5 and 6.8. Determination of 
drug release kinetics profiles of carrageenan-based hard-
shell capsules utilized the Noyes-Whitney and Peppas-
Sahlin modification rules for zero-order. The drug release 
from carrageenan-based capsules followed zero-order 
kinetics, especially at pH 6.8, and was compared to the 
Higuchi model. Salicylamide in CA hard-shell capsules at 
a pH 6.8 had a release rate constant (kH) of 2.91 %(ppm/
ppm) min-1/2, while the release rate constant of CS was 0.36 
%(ppm/ppm) min-1.
Keywords: Dissolution; Drug release kinetics; 
Salicylamide; k-Carrageenan; Capsule.
1  Introduction
Commercially available hard-shell capsules are generally 
made from gelatin, which is produced from bone and 
skin of cows, pigs or buffalos. Gelatin hard-shell capsules 
were introduced in 1931 by Arthur Cotton [1]. The first 
non-gelatin hard-shell capsule was produced in 1989 
with the trademark of Vegicaps, and it was made from a 
material, hydroxypropyl methylcellulose (HPMC), that 
is appropriate for vegetarians or vegans. As an addition, 
carrageenan-based non-gelatin hard-shell capsules have 
been patented and produced, i.e. Quali-V [2]. 
Carrageenan is one of the most important commercial 
marine products, along with alginates and agars. Indonesia 
and the Philippines are two countries that produce much 
of the carrageenan for the rest world [3]. It is extracted from 
red seaweeds, especially from the Rodhophyceae family, 
including Chondruscripus, C. ocellatus, Eucheuma cottonii, 
E. spinosum, E. gelatinae, Furcellaria fatigiata, Gigartina 
stellata, G. acicularis, G. pistillata, G. canaliculata, G. 
chamissol, G. radula, G. skottsbergii, Gymnogongrus 
furcellatus, Hypneamusciformis and H. spicifera [4]. 
Carrageenan is a sulfated polysaccharide that 
is classified based on the position of the link of 
anhydrogalactose bond and the number and position 
of ester sulfate.  Subclasses of carrageenans include α, 
β, k, i, and q [5] as well as m and ν [6]. k-Carrageenan is 
mainly obtained from tropical seaweed of the Eucheuma 
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cottonii or Kappaphycus alvarezii species.  Commercial 
k-carrageenan contains an ester sulfate and D-galactose-4-
sulfate 3,6-anhydro-D-galactose at levels of approximately 
25 to 30% and 28-35%, respectively [5,6]. The molecular 
weight of carrageenan is in the range of 100 to 1000 kDa. 
It is a strong anionic polymer possessing excellent gelling, 
thickening, stabilizing [5,7] and emulsifying [6] properties. 
Carrageenan is also used for non-foods industries, 
including as a pharmaceutical excipient and as a medicine 
[6]. Carrageenan has some bioactivities, such as antioxidant, 
antimicrobial towards Salmonella typhimurium and E. coli 
O157:H7 strains, immunomodulatory, antiviral, antitumor, 
anticoagulant and antithrombotic properties [8]. It is 
regarded as a nontoxic and nonirritating agent for use in 
nonparenteral formulations, and it is well known as an 
anti-inflammatory agent [9]. Alginate is used as a dietary 
fiber, and it can stimulate the immune system, reduce 
intestinal absorption, increase satiety, reduce glycemic 
index and modulate colonic microflora [8]. Alginate can 
be consumed as a beverage to reduce the blood sugar level 
[10]. 
Due to these important consumer-targeted properties, 
combinations of carrageenan-alginate and carrageenan-
starch are being developed as new products as non-gelatin 
nutraceutical (nutrition and pharmaceutical) hard-
shell capsules. This nutraceutical capsule offers unique 
inherent acid-resistant natural polymer properties. Thus, 
the capsule resists disintegration in the stomach but 
opens immediately once the pH rises above 4.5, out of 
the acidic environment of the stomach. Disintegration 
starts approximately 25 minutes after the ingestion of 
the capsule, and the dissolution of drugs begin after 50 
minutes. The complete release of the gelatin hard-shell 
capsule takes place in the small intestine around 20 min 
after the onset of release when the pH shifts more to a 
neutral pH of 6.8. Therefore, the nutraceutical capsule is 
acid-resistant and delivers to the small intestine [11].
In vitro dissolution is an important factor in drug 
absorption, distribution, metabolism and excretion 
(ADME). Dissolution is defined as the rate of transfer 
of mass from the dosage form into a liquid medium 
at a suitable temperature for standardization [12]. 
Many kinetics models have been used to describe drug 
dissolution and release from solid dosage forms [13]. 
Drug release can be divided into several modes, including 
immediate release, modified-release, extended-release, 
controlled-release and pulsatile-release [12]. Salicylamide 
is a non-steroidal and anti-inflammatory agent; it has 
analgesic, antipyretic and platelet inhibitory actions. 
Salicylamide is stable in acid and weak base, so it can 
be used as a model of drug release kinetics. Carrageenan 
can be used to control the release of drugs, improve the 
dissolution of drugs and has been tested for its potential 
use in broader biomedical application [6,14].
Information about drug release kinetics of carrageenan-
based hard-shell capsules is still limited.  There are 
reports on drug release properties during diffusion from 
layer-by-layer self-assembled κ- carrageenan-chitosan 
nanocapsules [15], application of κ-carrageenan as a 
sustained-release matrix in floating tablets containing 
sodium salicylate [16] and drug release kinetics and 
front movement in matrix tablets containing diltiazem 
or metoprolol/λ-carrageenan complexes [17]. However, 
none of these reports investigated drug release kinetics 
from nutraceutical hard-shell capsules. This paper reports 
the study of disintegration, dissolution and drug release 
kinetic profiles of k-carrageenan-based nutraceutical 
hard-shell capsules containing salicylamide. 
2  Experimental Method
2.1  Materials
Food grade k-carrageenan and sodium alginate were 
purchased from Kappa Carrageenan Nusantara, Inc., 
Pasuruan, Indonesia. Carrageenan-alginate (CA) and 
carrageenan-starch (CS) hard-shell capsules were 
prepared in Kapsulindo Nusantara, Inc., Bogor, Indonesia. 
All water used was deionized.
2.2  Preparation of Hard-Shell Capsules
Carrageenan and alginate were combined and mixed 
into the water gently at room temperature. Then, the 
temperature was raised to 70oC to create a homogeneous 
solution. The solution was poured into a bath and printed 
using zero size dipping bars and dried at room temperature 
for 4 h to produce capsules. The same procedure was 
conducted to create CS capsules.
2.3  Disintegration Test
The disintegration of capsules was tested using a 
disintegration tester type Veego-202397. Six chambers 
were filled with 900 mL of water. Six carrageenan-based 
(CA and CS) capsules were put in each basket and heated 
at 37±0.5oC. The apparatuses were slowly rotated until 
hard-shell capsules were disintegrated completely.
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2.4  Dissolution Test and Release Kinetics 
Analyses
An Erweka Dissolution Tester type DT 820 was adjusted 
to 37oC and rotated at 100 rpm. Three of each of the 
carrageenan-based (including CA and CS) zero size 
capsules were filled with 100 mg of salicylamide and put 
in the basket holder, which contained 900 mL of medium. 
The dissolution media was created as described by the 
United States Pharmacopeia (USP) at pH 1.2 (0.1 mol/L 
HCl), pH 4.5 (citrate buffer) and pH 6.8 (phosphate buffer). 
All media were calibrated with a pH meter prior to each 
assay.  Samples (5 mL) were taken after 5, 10, 15, 20, 30, 
45 and 60 min, and volumes were maintained by refilling 
with 5 mL of media. All samples were analyzed using a 
UV-Vis spectrometer at 298 and 299 nm for pH 4.5 and 1.2 
/ 6.8, respectively. The data were analyzed statistically to 
obtain dissolution and kinetics profiles in all media. Drug 
release kinetics profiles utilized the Noyes-Whitney rules 
for zero-order calculation. The best profile of the graphs 
from the Noyes-Whitney and Peppas-Sahlin equations 
were used to determine kH using the Higuchi model.
Ethical approval: The conducted research is not 
related to either human or animal use.
3  Results and Discussion
3.1  Disintegration of CA and CS
The CA and CS hard-shell capsules disintegrated 
completely by 12.80 and 25.79 min, respectively as 
shown in Table 1. All of the capsules ruptured within 
30 min, which meets the USP recommendation for the 
disintegration of dietary supplements [19]. 
Starch is a semicrystalline material that contains 
the crystalline form of a linear structure of amylose and 
the amorphous form of branched amylopectin [20], 
while sodium alginate is a linear unbranched copolymer 
composed of β-D-mannuronic acid (M) and α-L-guluronic 
acid (G) linked by 1→4 glycosidic bonds and appears as 
an amorf [21]. Therefore, the structure of CS is more rigid 
than CA. This rigid structure likely prevents CS from 
being ruptured by the medium better than CA; this model 
correlates with the higher disintegration time of  CS relative 
to CA. As an addition, Glube et al. reported that hard-shell 
capsules made of hypromellose (HPMC)–carrageenan 
that contained green tea extracts disintegrated within 20 
min [19]. It is seen that the order of disintegration time 
from the slowest to the fastest time would be  CS > HPMC-
carrageenan > CA > gelatin. Therefore, relative to gelatin, 
the disintegration time of CA was better than other 
materials, which was HPMC in this case.
Table 1: Disintegration times of capsules.
Capsules CA (min) CS (min)
1 11.28 20.04
2 11.28 25.52
3 12.13 27.02
4 13.47 27.02
5 14.33 27.58
6 14.33 27.58
Mean 12.80 25.79
Standard Deviation 1.43 2.92
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Figure 1: Dissolution profile of salicylamide released from (a) CA and (b) CS capsules at pH 1.2, 4.5 and 6.8. The dissolution of the drug 
capsules was carried out in triplicate for each formulation, and results are reported as averages +/- standard deviation. 
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3.2  Dissolution and release kinetics analyses 
of salicylamide released from CA and CS
The dissolution of salicylamide from hard-shell capsules of 
CA reached approximately 70% at pH 4.5 within one hour 
(Figure 1a), while in CS (Figure 1b), it was poorly dissolved 
in all of the media conditions compared to CA hard-shell 
capsules. The disintegration test does not require the drug 
to be inside the capsules (USP NF-32), while the dissolution 
test requires it (USP 711). The salicylamide substance 
enters into the solvent to produce a solution. Interactions 
(especially hydrogen bonds) between salicylamide and CA 
and CS might slow the solvation process. The percentage 
of dissolution of salicylamide from the hard-shell capsules 
of CA and CS at pH 1.2, 4.5 and 6.8 is shown in Figure 1. In 
general, salicylamide dissolution increased over time in all 
three media. 
The differences of dissolution may be due to a 
variety of characteristics of the matrix material, such as 
composition, structure, gelling, pH, temperature and 
ionic strength [22]. Chiwele et al. reported that the empty 
hard-shell capsules of gelatin, gelatin-PEG (polyethylene 
glycol) and HPMC at pH under 5.8 and at 10oC to 55oC 
dissolved rapidly, while gelatin and gelatin-PEG did not 
dissolve at a temperature below 30oC [23]. There was a 
significant increase in dissolution for capsules at pH 4.5 
shown in Figure 1b. One possible explanation could be 
that the capsules were significantly dissolved at 50 min, 
which increased the dissolution of salicylamide into the 
medium exponentially.
Many mathematical models for determining drug 
release from solid dosage forms are available: the Noyes-
Whitney rule, Higuchi, Hixson-Crowell, Korsmeyer-
Peppas, Baker-Romdale, Weibull, Hopenberg and 
Gompertz model are used routinely. In this experiment, 
the mathematical model of drug release used is shown 
in equation (1), a modification of the Noyes-Whitney 
equation, for zero-order release kinetics calculations 
[13,18].
Qt = Q0 + K0 t (1)
In equation (1), Qt is the amount of drug dissolved in 
solution at time t, Q0 is the initial amount of drug in the 
solution (typically, Q0 = 0), and k0 is the zero-order release 
constant. Costa et al. reported that the dosage forms of 
drugs following zero-order release are the ideal model of 
drug release [13]. The logarithmic form of equation (1) is 
shown in equation (2): 
log Qt =log K0+log t (2)
The kinetics of the release of the drug can be classified 
as zero or first-order. The drug release in this experiment 
used the Noyes-Whitney equation model. Figure 2 
compares a zero-order kinetic model to the drug release 
profile of salicylamide from CA hard-shell capsules. Since 
the only pH where salicylamide dissolved up to 80% was 
4.5 (Figure 2b), there was only one kinetic profile that 
could be calculated. The salicylamide was released in 
the CA capsules more quickly at pH 4.5, and Figure 2b 
also shows linearity. The zero-order release constants 
of salicylamide in CA at pH 1.2 (Figure 2a) and 4.5 were 
3.28 and 4.14 ppm/min (Table 2). The zero-order release 
constant of salicylamide in CA at pH 4.5 (Figure 2b) was 
4.14 ppm/min (Table 2). Therefore, we suggest further 
study of CA capsules at pH 4.5. Even though CA capsules 
had poor solubility at pH 1.2 and 6.8 (Figure 2c), we also 
suggest further study for medicines with long release time 
that would be suitable for these features.
Table 2. The ko and R2 value of zero-order kinetics of carrageenan-
based hard-shell capsules
pH k0 CA
ppm/min
R2 k0 CS
ppm/min
R2
1.2
4.5
6.8
3.28
4.14
0.46
0.90
0.98
0.84
0.058
0.23
0.067
0.87
0.92
0.82
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Figure 2: The zero-order drug release profile of salicylamide from CA capsules at pH (a) 1.2, (b) 4.5, and (c) 6.8.  
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What seems interesting is that the capsules exhibit 
good solubility in a weakly acidic environment but not 
in either strongly acidic or more basic environments. 
No research to support or explain these results could be 
found. However, one possible explanation could be that 
the solubility of carrageenan might be affected by its 
sulfate groups. A citrate buffer solution that created a 
weakly acidic environment might increase its solubility 
by decreasing intramolecular hydrogen bonding in 
carrageenan’s secondary structure, as this structure is the 
main feature of carrageenan’s gelling ability [23]. Thus, 
when intramolecular interactions are broken, carrageenan 
would be expected to dissolve easily. This might not 
happen at pH 1.2 and pH 6.8, where HCl and phosphate 
buffers were used, because the buffer molecule itself could 
not form hydrogen bonds.  Finally, since CS capsules have 
poor solubility at all pH values examined, release kinetic 
profiles could not be developed for the material due to 
Peppas-Sahlin’s rules [25]. Thus, we suggest that further 
research related to the dissolution time of CS capsules for 
more than 1 h should be conducted. The zero-order kinetic 
constants for CA capsules were 3.27 and 4.14 ppm/min 
(Table 2) for pH 1.2 and 4.5, respectively.  
Analysis of drug release from carrageenan-based 
hard-shell capsules resulted in linear graphs that followed 
zero-order kinetics in the Noyes-Whitney model and were 
good mathematically and kinetically modeled at pH 6.8. 
This pH was applied to investigate the diffusion coefficient 
using the Higuchi model. Figure 3 represents the drug 
release of salicylamide in CA and CS hard capsules at pH 
6.8 using the Higuchi model [12]. The graphs resulted from 
the Higuchi model calculation (Figure 3) represented the 
release kinetics process of drugs that were released from a 
swellable polymer, where the graph was plotted from the 
amount of drug released against the square-root of time. 
The simplified mathematical form of the Higuchi model is 
shown by equation (3). 
Qt = kH √t (3)
In this equation, Qt is the amount of drug released at 
time t, and kH is the release rate constant for the Higuchi 
model. This model features the release from both planar 
and spherical surfaces, where two geometric systems have 
been considered: the undirectional leaching of a simple 
planar surface and three-dimensional leaching from a 
spherical pellet [26].
We chose to examine the data at pH 6.8 because of 
its good linearity in Figure 3b compared to the other 
results, even though the capsules were less soluble in this 
environment. Another reason to be highlighted was that 
the only parameter affected by the acidity was the rate of 
release, but all capsules dissolved eventually. Therefore, 
capsules could still be used at every pH for any drug that 
meets compatible properties.
The graph shows that salicylamide in CA is released 
with a rate constant (kH) of 2.91 %(ppm/ppm) min-1/2 (Figure 
3a), while CS was 0.36 %(ppm/ppm) min-1/2 (Figure 3b) at 
pH 6.8. At pH 6.8, the hard-shell capsule of CA has a bigger 
kH than does CS. They had diffusion coefficients that were 
large, and CA releases more under that condition. Finally, 
developments are needed for this study to be applied in 
the human body. In vivo studies must be performed to 
support this information with respect to toxic dosages. 
One example might be work similar to that carried out 
by Zhang et al. in which they studied nanoparticular 
melamine in a mouse model [27].
4  Conclusions
CA had lower stability or was more readily dissolved 
in a weaker acid medium (pH 4.5) than other natural, 
carbohydrate-based polymers. Salicylamide in CA was 
released into the acidic medium more readily than CS. 
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Figure 3: The Higuchi model of drug release of salicylamide in hard-shell (a) CA and (b) CS capsules at pH 6.8
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One reason to explain the phenomenon is that starch 
has smaller membrane pores and is more stable in a 
strongly acidic medium (pH 1.2). Salicylamide, in CS, 
results in a smaller percentage of drug release than that 
of CA. Dosage forms that prolong release can maintain 
drug concentrations for longer periods in a more optimal 
therapeutic range while minimizing toxicity.
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